Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 17 Jan 2023 for Immunome Inc., €51k. Read the official filing
Filing timeline
BuySaleMichael Lefenfeld
Insider track record
Disclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-31.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Michael Lefenfeld: trading record in brief
Michael Lefenfeld (board member) discloses dealings in Immunome Inc. to SEC (Form 4). In total, 2 filings cover trades dated from 24 May 2021 to 15 January 2023.
No open-market sale appears; the market trades are 1 purchase worth €8,744. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant.
The record was last updated on 17 January 2023 with a share grant (€51k) in Immunome Inc. The last purchase on record was published on 26 May 2021, which is 1,972 days ago. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Michael Lefenfeld
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
13,875 shares@ US$4.0074.5% of flowCommon StockSEC:0001104659-23-004005:0
600 shares@ US$17.8014.6% of flowCommon StockSEC:0001104659-21-072621:0
Canonical exit: 22 Aug 2021 (T+90)
2 of 2 declarations
